On January 22nd, STENOCARE announced the outcome of the conditional rights issue, which was subscribed to approximately 37.7%. Moreover, guaranteed commitments from Exelity AB amounting to 7.3% will be activated to achieve a subscription rate of 45%, which will provide STENOCARE with DKK 9.1m in gross proceeds in order to execute on the STENOCARE 3.0 strategy.

In summary, we view the outcome of the rights issue as reasonable, given the current market climate. We expect STENOCARE to utilize the net proceeds, in addition to repaying the loan, to scale up sales, including education on the benefits of the new innovative Astrum oil. After several sales-challenging years for STENOCARE, partly due to a more sluggish market than expected, it is critical for the company to prove the company’s ability to increase sales in different markets. We see the new wholehearted focus on becoming a distributor, and the benefits of Astrum oil, as important factors for achieving this success.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
 
This is a press release from Analyst Group regarding the publication of a comment on STENOCARE. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.